AnalystsAndrew PetersAndrew Peters's Stock Forecasts
AnalystsAndrew Peters
Analyst Ranking
Top 23%
#1107 out of 4875 analysts
Average Return
+34.12%
Win Rate
75%9 out of 12
Risk vs Reward
Poor
Good
Andrew Peters's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Gilead Sciences IncGILD | +115.57% | $28.65 | $61.75 | 2012-08-02 - 2013-08-02 | Strong Buy |
Gilead Sciences IncGILD | +96.27% | $28.99 | $56.89 | 2012-08-15 - 2013-08-15 | Strong Buy |
Gilead Sciences IncGILD | +91.40% | $33.61 | $64.32 | 2012-09-19 - 2013-09-19 | Strong Buy |
Gilead Sciences IncGILD | +88.47% | $36.35 | $68.50 | 2012-11-13 - 2013-11-13 | Strong Buy |
Esperion Therapeutics IncESPR | +17.09% | $36.93 | $43.24 | 2018-05-03 - 2019-05-03 | Strong Buy |
Andrew Peters Analyst Color
Get additional color on Andrew Peters's coverage of popular stocks
Andrew Peters's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Esperion Therapeutics IncESPR | 3 | Strong Buy | $75.00 | N/A | Maintains | 7 years ago |
Prothena Corp Public Ltd CoPRTA | 1 | Strong Buy | $16.00 | N/A | Maintains | 7 years ago |
Biomarin Pharmaceutical IncBMRN | 1 | Strong Buy | $124.00 | N/A | Maintains | 7 years ago |
Alexion Pharmaceuticals IncALXN | 1 | Strong Buy | $161.00 | N/A | Maintains | 7 years ago |
Exelixis IncEXEL | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Gilead Sciences IncGILD | 5 | Strong Buy | $79.00 | N/A | Initiates Coverage On | 8 years ago |
Bioverativ IncBIVV | 1 | Hold | $65.00 | N/A | Initiates Coverage On | 8 years ago |
Biogen IncBIIB | 1 | Strong Buy | $315.00 | N/A | Initiates Coverage On | 8 years ago |
Amgen IncAMGN | 1 | Hold | $172.00 | N/A | Initiates Coverage On | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.